HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Atossa Therapeutics (ATOS) with a $4 price target.

April 02, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics maintains a Buy rating and a $4 price target from HC Wainwright & Co.
The maintenance of a Buy rating and a $4 price target by a reputable analyst firm like HC Wainwright & Co. typically signals confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100